FDA Cell and Gene Therapy Roundtable June 5, 2025 Roundtable Participants
Jeff Allen, PhD Present and CEO Friends of Cancer Research
Ron Bartek Co-founder and President Friedreich's Ataxia Research Alliance
Allyson Berent, DVM, DACVIM Chief Scientific Officer Foundation for Angelman Syndrome Therapeutics Co-Director Angelman Syndrome Biomarker and Outcome Measure
Catherine Bollard, MBChB, MD Senior Vice President and Chief Research Officer Director, Center for Cancer and Immunology Research Professor of Pediatrics and Immunology Children's National and The George Washington University
Thomas Cahill, MD, PhD Founder and Managing Partner Newpath Partners
Andrew M. Cameron MD, PhD Director Department of Surgery The Johns Hopkins University School of Medicine
Paula Cannon, PhD Distinguished Professor of Microbiology and Immunology Keck School of Medicine University of Southern California
Terence R. Flotte, MD Professor, Provost, Dean of UMass Chan Medical School President, American Society of Gene and Cell Therapy
Charles A. Gersbach, PhD John W. Strohbehn Distinguished Professor Department of Biomedical Engineering Director, Center for Advanced Genomic Technologies Duke University
Bambi Grilley, RPh, CCRC, CCRP, CIP, RAC Director, Clinical Research and Early Product Development Center for Cell and Gene Therapy Professor, Pediatrics Baylor College of Medicine Chief Regulatory Officer International Society for Cell & Gene Therapy
Timothy Hunt, JD Chief Executive Officer Alliance for Regenerative Medicine
Carl H. June, MD Richard W. Vague Professor in Immunotherapy Department of Pathology and Laboratory Medicine Director Center for Cellular Immunotherapies Director, Parker Institute for Cancer Immunotherapy Perelman School of Medicine University of Pennsylvania Smilow Center for Translational Research
Donald B. Kohn, MD Distinguished Professor: - Microbiology, Immunology and Molecular Genetics - Pediatrics, Hematology/Oncology - Molecular and Medical Pharmacology University of California, Los Angeles
Brett Kopelan, MA Executive Director The Dystrophic Epidermolysis Bullosa Research Association of America
David Liu, PhD Richard Merkin Professor and Director of the Merkin Institute for Transformative Technologies in Healthcare Director of the Chemical Biology and Therapeutic Sciences Program Core Institute Member and Vice-Chair of the Faculty, Broad Institute Investigator, Howard Hughes Medical Institute Thomas Dudley Cabot Professor of the Natural Sciences and Professor of Chemistry & Chemical Biology, Harvard University
Jayme Locke MD, MPH Vice President, Medical Development Xenotransplantation United Therapeutics
Crystal Mackall, MD Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine Founding Director, Stanford Center for Cancer Cell Therapy Director of the Parker Institute for Cancer Immunotherapy Stanford University
Rachel McMinn, PhD Founder and CEO Neurogene
Sean J. Morrison, PhD Investigator, Howard Hughes Medical Institute Director, Children's Research Institute at UT Southwestern University of Texas Southwestern Medical Center Dallas, Texas Chair of Public Policy Committee International Society for Stem Cell Research
Terry Pirovolakis CEO & Founder Elpida Therapeutics
Vinayak Prasad, MD, MPH Director Center for Biologics Evaluation and Research U.S. Food and Drug Administration
Michelle Rengarajan, MD, PhD Physician-Scientist and Attending Endocrinologist Massachusetts General Hospital Instructor in Medicine Harvard Medical School
Shengdar Q. Tsai, PhD Associate Member, Department of Hematology, St. Jude Children's Research Hospital Co-chair, Steering Committee of NIH Somatic Cell Genome Editing Consortium
Fyodor Urnov, PhD Professor of Molecular Therapeutics at University of California, Berkeley Scientific Director at Innovative Genomics Institute
Nicole Verdun, MD Super Office Director Office of Therapeutic Products Center for Biologics Evaluation and Research U.S. Food and Drug Administration
AI
Market Data 
Markets 
